Merck adds oncolytics combo study to its huge Keytruda effort

Merck ($MRK) and Houston-based DNAtrix have struck a deal to collaborate on a combination study of the pharma giant's checkpoint inhibitor Keytruda with the biotech's oncolytics immunotherapy DNX-2401. No deal terms were disclosed, but longtime observers will note that Merck R&D chief Roger Perlmutter was an early advocate of oncolytics' potential when he was running the research arm at Amgen ($AMGN) (now pursuing an approval for T-Vec). The oncolytics approach is designed to spur a viral attack that can implode cancer cells while launching an immune system attack. And Perlmutter has maintained a huge commitment to expanding on a pioneering approval for Keytruda. A spokesperson for Merck notes that the company is conducting more than 130 clinical trials for Keytruda across more than 30 tumor types. There are 80 ongoing and planned combo studies. Investigators have been enrolling more than 22,000 patients for the monotherapy and in combination with other therapies. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.